For: | Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14(1): 119-139 [PMID: 35126843 DOI: 10.4254/wjh.v14.i1.119] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i1/119.htm |
Number | Citing Articles |
1 |
Reda Albadawy, Amany Helmy Hasanin, Sara H. A. Agwa, Shaimaa Hamady, Yasmin M. Aboul-Ela, Mona Hussien Raafat, Samaa Samir Kamar, Mohamed Othman, Yahia A. Yahia, Marwa Matboli. Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death. International Journal of Molecular Sciences 2022; 23(17): 10148 doi: 10.3390/ijms231710148
|
2 |
Jialei Fu, Sangah Shin. Dietary patterns and risk of non-alcoholic fatty liver disease in Korean adults: a prospective cohort study. BMJ Open 2023; 13(1): e065198 doi: 10.1136/bmjopen-2022-065198
|
3 |
Vitalina V. Ivachevska, Mykhailo M. Ivachevskyi, Mykhailo M. Hechko, Ivan I. Myhovych, Olga S. Blaga. EFFICACY OF COMPREHENSIVE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PREDIABETES. Wiadomości Lekarskie 2023; 76(3): 581 doi: 10.36740/WLek202303119
|
4 |
Lin Jia. Dietary cholesterol in alcohol-associated liver disease. Immunometabolism 2023; 5(2): e00026 doi: 10.1097/IN9.0000000000000026
|
5 |
强江 郭. Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease. Advances in Clinical Medicine 2024; 14(03): 561 doi: 10.12677/ACM.2024.143739
|
6 |
Lucia M. Chávez-López, Gabriela I. Carballo-López, Karina del Carmen Lugo-Ibarra, Ana B. Castro-Ceseña. A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis. RSC Medicinal Chemistry 2024; 15(8): 2622 doi: 10.1039/D4MD00420E
|
7 |
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, Joseph M Pappachan. Management of metabolic-associated fatty liver disease: The diabetology perspective. World Journal of Gastroenterology 2023; 29(1): 126-143 doi: 10.3748/wjg.v29.i1.126
|
8 |
Chrysoula Boutari, Christos V. Rizos, George Liamis, Ioannis Skoumas, Loukianos Rallidis, Anastasia Garoufi, Genovefa Kolovou, George Sfikas, Konstantinos Tziomalos, Emmanouil Skalidis, Vasileios Kotsis, Michalis Doumas, Kimon Stamatelopoulos, Vaia Lambadiari, Panagiotis Anagnostis, Amalia Boufidou, Vasiliki Giannakopoulou, Georgia Anastasiou, Ermioni Petkou, Charalambos Vlachopoulos, Ioanna Dima, Georgios Fakas, Konstantinos A. Papathanasiou, Achilleas Attilakos, Vana Kolovou, Charalambos Koumaras, Dimitrios Agapakis, Evangelos Zacharis, Christina Antza, Haralampos Milionis, Evangelos Liberopoulos, Christos S. Mantzoros. The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients. Clinical Nutrition 2024; 43(12): 84 doi: 10.1016/j.clnu.2024.10.020
|
9 |
Ramiro Manzano‐Nunez, Jesús Rivera‐Esteban, Jordi Navarro, Juan Bañares, Elena Sena, Jörn M. Schattenberg, Jeffrey V. Lazarus, Adria Curran, Juan M. Pericàs. Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa. Journal of the International AIDS Society 2023; 26(3) doi: 10.1002/jia2.26072
|
10 |
Stefania Cannito, Umberto Dianzani, Maurizio Parola, Emanuele Albano, Salvatore Sutti. Inflammatory processes involved in NASH-related hepatocellular carcinoma. Bioscience Reports 2023; 43(1) doi: 10.1042/BSR20221271
|
11 |
Zahra Eslami, Samaneh Sadat Aghili, Amir Ghaleh Ghafi. Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients. Chonnam Medical Journal 2024; 60(1): 13 doi: 10.4068/cmj.2024.60.1.13
|
12 |
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros, Ali Eid. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacological Reviews 2024; 76(3): 454 doi: 10.1124/pharmrev.123.001087
|
13 |
Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology. Atherosclerosis 2024; 392: 117523 doi: 10.1016/j.atherosclerosis.2024.117523
|
14 |
J. Fu, Z. Mu, L. Sun, X. Gao, X. Hu, S. Xiu. Chinese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease have lower serum osteocalcin levels compared to individuals with type 2 diabetes mellitus and no liver disease: a single-center cross-sectional study. Journal of Endocrinological Investigation 2022; 45(12): 2275 doi: 10.1007/s40618-022-01861-z
|
15 |
Shuai Yuan, Jie Chen, Marijana Vujkovic, Kyong-Mi Chang, Xue Li, Susanna C Larsson, Dipender Gill. Effects of metabolic traits, lifestyle factors, and pharmacological interventions on liver fat: mendelian randomisation study. BMJ Medicine 2022; 1(1): e000277 doi: 10.1136/bmjmed-2022-000277
|
16 |
Anna Licata, Giuseppina T. Russo, Annalisa Giandalia, Marcella Cammilleri, Clelia Asero, Irene Cacciola. Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. Journal of Personalized Medicine 2023; 13(3): 558 doi: 10.3390/jpm13030558
|